DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Fotemustine is an investigational drug.
There have been 16 clinical trials for Fotemustine. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2012.
The most common disease conditions in clinical trials are Melanoma, Uveal Neoplasms, and Neoplasm Metastasis. The leading clinical trial sponsors are Bristol-Myers Squibb, Mingzhi Zhang, and Hoffmann-La Roche.
There is one US patent protecting this investigational drug and twenty-five international patents.
Recent Clinical Trials for Fotemustine
|Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma||Mingzhi Zhang||Phase 4|
|A Phase I/IIa Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT||Genenta Science||Phase 1/Phase 2|
|MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients||Azienda Sanitaria di Firenze||Phase 2/Phase 3|
Top disease conditions for Fotemustine
Top clinical trial sponsors for Fotemustine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Fotemustine||Start Trial||Heat shock protein 70 (hsp-70) receptor ligands||Duke University (Durham, NC)||Start Trial|
|Fotemustine||Start Trial||Compounds and their methods of use||Agios Pharmaceuticals, Inc. (Cambridge, MA)||Start Trial|
|Fotemustine||Start Trial||Anti-FGFR3 antibodies and methods using same||Genentech, Inc. (South San Francisco, CA)||Start Trial|
|Fotemustine||Start Trial||Bispecific antigen-binding constructs targeting HER2||Zymeworks Inc. (Vancouver, CA)||Start Trial|
|Fotemustine||Start Trial||Method of diagnosing and treating cancer using B-catenin splice variants||The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)||Start Trial|
|Fotemustine||Start Trial||Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers||Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Fotemustine||World Intellectual Property Organization (WIPO)||2015148714||2034-03-25||Start Trial|
|Fotemustine||Eurasian Patent Organization||201691896||2034-03-21||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|